External medicine for treating seborrheic alopecia

Abstract

The present invention relates to an external-use medicine for treating seborrheic alopecia. The external-use medicine comprises an active ingredient and medically acceptable excipients. The active ingredient is prepared from the following raw materials in percentage by weight: 13.6-22.8% of American ginseng, 12.8-20.8% of dandelion, 9.5-12.3% of salvia miltiorrhiza, 7.9-11.1% of red ginseng, 7.6-12.7% of astragalus, 4.4-7.3% of zanthoxylum bungeanum, 4.7-7.4% of pine needles, 3.9-6.2% of kelp, 3.2-5.4% of panax notoginseng, 3.3-5.5% of safflower, and 3.4-5.8% of ligusticum chuanxiong. The external-use medicine has a significant effect in treating seborrheic alopecia.

Description

Technical Field

[0001] The present invention relates to a medical preparation, in particular to a medicine containing an unidentified structure from traditional Chinese medicine, which is suitable for treating hair loss. Background Art

[0002] Hair loss is a common skin disease, with seborrheic alopecia and alopecia areata being the most common types. Both types of hair loss negatively impact appearance. With socioeconomic development, rising living standards, and intensified social competition, the incidence of hair loss has been increasing year by year. Minoxidil is a vasodilator that induces vasodilation, increases blood circulation, and promotes overexpression of vascular endothelial growth factor. However, its primary side effects on the scalp are itching, redness, and dandruff, ultimately leading to facial hirsutism. Minoxidil thus has significant toxic side effects. While some Chinese herbal medicines are toxic, their toxicity is significantly reduced when combined in a formula, and they also exhibit enhanced efficacy compared to individual herbs. Therefore, herbal combinations formulated according to Traditional Chinese Medicine theory are of great significance for the treatment of hair loss.

[0003] Seborrheic alopecia is the most common type of hair loss, also known in Western medicine as androgenic alopecia. While there's no consensus on its syndrome classification, it's broadly categorized as damp-heat accumulation, liver and kidney deficiency, blood-heat and wind-excess, blood deficiency and wind-dryness, and liver depression and blood deficiency, with liver and kidney deficiency being the most common. Regardless of the syndrome type, oiliness and itching are prominent symptoms. Topical preparations, unlike oral medications, act directly on the lesion, addressing the symptoms before the underlying cause. Providing a favorable growth environment for hair follicles is crucial and essential. Currently, most traditional Chinese medicine hair growth preparations focus on promoting blood circulation, removing blood stasis, and unblocking the meridians, utilizing high doses of blood-activating and nourishing herbs. For example, the article "Dermoscopic Observation of the Efficacy of Comprehensive Therapy for Severe Alopecia Areata and Its Effect on Cytokines" discloses a hair-blackening tincture prepared in a hospital. This tincture is made from American ginseng, Panax notoginseng (Panax ginseng), Chuanxiong, Astragalus, Sichuan pepper (Zanthoxylum bungeanum), Panax notoginseng (Panax notoginseng), Carthamus tinctorius, Salvia miltiorrhiza, and Licorice (a 2013 master's thesis by Liang Jiafen). Upon review, the aforementioned hair-blackening tincture is the one listed in Guangdong Provincial Drug Administration approval document Yue ZB20111999. Its specific formula is: American ginseng 18.5g, red ginseng (Panax ginseng) 18.5g, Panax notoginseng 9.3g, Carthamus tinctorius 19g, Sichuan pepper 15g, Licorice 19g, Astragalus 37g, Chuanxiong 37g, and Salvia miltiorrhiza 28g. As can be seen from the above prescription, it reuses Radix Astragali and Rhizoma Chuanxiong. Radix Astragali is slightly warm in nature, enters the spleen and lung meridians, strengthens the spleen and replenishes qi, and replenishes qi to promote blood circulation; Rhizoma Chuanxiong is warm in nature, enters the liver, gallbladder, and pericardium meridians, is a blood-QI medicine, pungent and dispersing and draws blood upward, the two are matched but can invigorate blood circulation and dredge the meridians, invigorate qi and lift, promote blood circulation in the head and face, and the head circulation metabolism is accelerated, and nutrients are transported to hair follicles, promote hair growth. As can be seen from the above-mentioned black hair tincture that reuses the medicine of promoting qi and blood circulation and dredge the meridians, although it can dissipate blood stasis, promote blood circulation, and help hair follicles to draw nutrients, the external environment of the hair follicle growth of the patient's head does not change, not only can't solve the root of kidney yin deficiency, kidney essence loss by transdermal absorption, the greasy scalp problem that is not solved is also not made of, and metabolites are accumulated in the scalp. Simultaneously, Rhizoma Chuanxiong is pungent and warm and dispersing, has the disadvantage of consuming blood and damaging yin, and is easily produced the feeling of sticky and greasy heat when used together with the Radix Astragali of warm nature, so the treatment effect of seborrheic alopecia is also not very ideal. Summary of the Invention

[0004] The purpose of the present invention is to provide an improved external medicine for treating seborrheic alopecia, which has a significant effect in treating seborrheic alopecia.

[0005] The technical solutions of the present invention for solving the above problems are as follows:

[0006] A topical medicament for treating seborrheic alopecia, comprising an active ingredient and medically acceptable excipients, wherein the active ingredient is made of the following raw materials in the following weight percentages:

[0007] American ginseng 13.6-22.8%, dandelion 12.8-20.8%, salvia miltiorrhiza 9.5-12.3%, red ginseng 7.9%-11.1%, astragalus 7.6-12.7%, zanthoxylum 4.4-7.3%, pine needle 4.7-7.4%, kelp 3.9-6.2%, Panax notoginseng 3.2-5.4%, safflower 3.3-5.5%, and Chuanxiong 3.4-5.8%.

[0008] The external-use medicine of the present invention, wherein the optimal ratio of the raw materials is:

[0009] American ginseng 19.2%, dandelion 16.6%, salvia miltiorrhiza 14.2%, red ginseng 8.9%, astragalus 10.2%, zanthoxylum 5.8%, pine needle 6.2%, kelp 5.6%, Panax notoginseng 4.3%, safflower 4.4%, and Chuanxiong 4.6%.

[0010] The external-use medicine of the present invention, wherein the active ingredient is prepared by the following method:

[0011] (1) Take the above raw materials, add 10-15 times the amount of water according to the proportion, and boil twice, each time for 2-4 hours;

[0012] (2) combining the two decoctions, filtering, and concentrating the filtrate under reduced pressure to form a thick paste to obtain the active ingredient; or drying the thick paste at 60-70° C. to obtain a dry paste to obtain the active ingredient.

[0013] The external-use medicine of the present invention is a commonly used tincture, powder or ointment.

[0014] The prescription of the external-use medicine of the present invention is composed of 11 raw materials. American ginseng and dandelion are combined as the main medicines, which can purge heat and calm the upper body, relieve stagnant qi, nourish yin and promote fluid production; salvia miltiorrhiza, red ginseng and astragalus are the auxiliary medicines, which have a suitable combination of cold and warm properties, purge while tonifying without damaging vital energy, help the main medicine to clear heat and promote fluid production, invigorate qi and generate blood, and nourish without drying out; Zanthoxylum bungeanum, Panax notoginseng, safflower, Chuanxiong, pine needles and kelp are the adjuvants, which travel along the liver and kidney meridians, assist the main medicine and auxiliary medicines in promoting blood circulation and removing blood stasis, promoting qi and calming the mind, and relieving the concurrent symptoms of itching. The combination of these medicines has the effects of clearing heat and dispelling fat, nourishing yin and invigorating qi, promoting blood circulation and unblocking menstruation, and calming the mind.

[0015] The prescription of the external-use medicine described in this application is improved from the prescription of the existing in-hospital preparation black hair tincture, and its improvements are: 1. From the perspective of medicinal taste, licorice is discarded and dandelion, pine needle and kelp are added; 2. From the perspective of prescription structure, American ginseng is reused and combined with the newly added dandelion with the merit of "black hair" as the monarch; the status of astragalus and Chuanxiong in the prescription is downgraded to one of the ministerial medicine and adjuvant medicine respectively; the added pine needle and kelp are combined with the Zanthoxylum bungeanum, Panax notoginseng, safflower and Chuanxiong in the original prescription as adjuvant. The above improvements can produce the following beneficial effects: First, American ginseng is paired with dandelion, and the two are used together as the monarch, which can clear away deficiency fire, benefit qi and blood, nourish yin and promote the production of body fluid, and can treat deficiency fire inflammation caused by liver and kidney yin deficiency, reduce excessive sebum secretion caused by heat forcing semen leakage, and change the original prescription's principle of "tonifying qi, activating blood circulation and unblocking meridians" to "clearing heat and removing fat, nourishing yin and benefiting qi". Second, reducing the dosage of Chuanxiong and Huangqi in the formula, and lowering their respective roles, can prevent patients from experiencing a feeling of stickiness, dryness, and heat. Third, adding pine needles and kelp to the original formula's four ingredients, Sichuan pepper, Panax notoginseng, safflower, and Chuanxiong, as adjuvants. Pine needles kill parasites and relieve itching, promote blood circulation, and calm the mind. Kelp is cold in nature and enters the kidney meridian, using like to nourish like, helping the monarch and ministers to promote blood circulation and dissolve stasis, promote qi circulation, and calm the mind. This makes the entire formula a combination of warming and cooling, purging and tonic, nourishing without drying, achieving the effects of clearing heat and dispelling fat, nourishing yin and replenishing qi, promoting blood circulation and menstruation, and calming the mind.

[0016] From the above analysis, it can be seen that the treatment method of the prescription of the present invention has been changed from the original "tonifying qi, activating blood circulation and unblocking meridians" to "clearing heat and removing fat, nourishing yin and replenishing qi", which significantly improves the external environment for hair follicle growth on the patient's head, pays attention to its symptoms, takes into account its root cause, treats both the symptoms and the root cause, and significantly improves the effect of treating seborrheic alopecia.

[0017] The therapeutic effect of the drug of the present invention on seborrheic alopecia can be further confirmed by the following experimental studies.

[0018] 1. Animal Experimentation

[0019] 1. Drugs and reagents:

[0020] Experimental group drugs: Take the tincture of Example 1 and add an appropriate amount of pure water to dilute it to 0.2 g of the raw material per ml. According to the average surface area of the adult scalp of 600 cm 2 Calculation: If the drug is given 2 to 3 times / day, 6 mL / time, then the daily skin dosage per unit area for adults is (6 mL / time × 3 times / day) ÷ 600 cm 2 =0.03mL / cm 2 The dosing area of mice in this experiment was 2cm×3cm=6cm 2 The dosage is (6 mL / time × 3 times / day) ÷ 600 cm 2 ×6cm 2 =0.18mL.

[0021] Control group drug: Wushen Hair Growth Tincture (product batch number 220302) purchased from Guangdong Provincial Hospital of Traditional Chinese Medicine was added with appropriate amount of pure water and diluted to a concentration of 200 mg / ml; the composition of the tincture was: American ginseng 18.5 g, red ginseng 18.5 g, Panax notoginseng 9.3 g, safflower 19 g, Zanthoxylum bungeanum 15 g, licorice 19 g, astragalus 37 g, Chuanxiong 37 g and Salvia miltiorrhiza 28 g.

[0022] Positive control group drug: 5% minoxidil tincture (Mandi), Zhejiang Wansheng Pharmaceutical Co., Ltd. Clinical usage is 1-2 times / day, 1 mL / time, with a daily dosage of less than or equal to 2 mL. In this experiment, each mouse was given 0.18 mL each time, once / day.

[0023] Modeling agent: Veet hair removal cream (purchased from Reckitt Benckiser Home Chemicals (China) Co., Ltd.).

[0024] 2 Experimental methods

[0025] 2.1 Experimental animals and groups

[0026] Twenty-four male C57BL / 6 mice weighing 18-22 g were purchased from Guangdong Medical Animal Experimental Center and randomly divided into a hair loss model group, a positive control group, an experimental group, and a control group, with 6 mice in each group.

[0027] 2.2 Hair removal model:

[0028] After the mice have adapted for a week, mark an area of 2 cm x 3 cm on their backs with a marker pen. Use an electric shaver to shave the hair within the marked area. Apply depilatory cream according to the instructions to remove any remaining hair and confirm that the mouse's hair is in the resting phase (the skin appears pink).

[0029] 2.3 Experimental drug administration

[0030] The hair removal model group was smeared with pure water, the positive control group was smeared with 5% minoxidil tincture, the experimental group was smeared with topical medication at a concentration of 200 mg / ml, and the control group was smeared with control medication at a concentration of 200 mg / ml, once a day, 180 μl each time, for 21 consecutive days.

[0031] 2.4 Measurement of new hair length in mice

[0032] At the end of the experiment (after 21 consecutive days of administration), 10 new hairs were randomly collected from the experimental area of each mouse using tweezers and a magnifying glass. The lengths of the 10 new hairs were measured using a vernier caliper, and the mean length of the new hairs of each mouse was calculated. Finally, the mean and standard deviation of each group were calculated and statistically analyzed.

[0033] 2.5 Determination of new hair weight in mice

[0034] On the last day of administration, all new hair was carefully shaved off with a shaver, weighed, and the mean and standard deviation of the weight of new hair of each group of mice were calculated and statistically analyzed.

[0035] 2.6 Determination of mouse hair growth integral

[0036] After successful modeling, scores were performed on the 3rd, 7th, 10th, 14th, 17th, and 21st days of drug administration according to the standards shown in the table below. Finally, the average score and standard deviation of the new hair growth score of each group on each observation day were calculated and statistically analyzed.

[0037] Table 1 Scoring criteria for mouse hair growth

[0038]

[0039] Note: If the new hair grows irregularly, it will be converted according to the area ratio

[0040] 2.7 Observation of mouse pathological tissues

[0041] At the end of the experiment, the skin of the experimental area on the back of the mice was taken for corresponding treatment to observe the condition of the hair follicles and skin tissue.

[0042] 2.8 Statistical methods:

[0043] The results are expressed as mean ± standard deviation (mean ± SD) and analyzed using SPSS statistical software. One-way ANOVA was used to compare differences between groups, and nonparametric tests were used for nonnormal distributions. P < 0.05 indicated statistical significance.

[0044] 2. Cell experiments

[0045] 1. Materials

[0046] MSCM culture medium (Boxi Biotechnology), PBS (Boster), RNAiso Plus (Takara), reverse transcription kit (Takara), fluorescent dye (Takara), dermal papilla cells (DPC)

[0047] 2. Cytotoxicity Assay

[0048] DPC was divided into a blank group and different concentration gradient groups of Example 1, with an initial concentration of 200 mg / ml and then diluted 2 times. 3Cells) were cultured with different concentrations of WFSFD for 0, 12, 24, 48 and 72 hours. Serum-free cell culture medium containing 0.5 mg / mL MTT was added to each recording point, 200 μL / well, and cultured at 37°C for 4 hours. After the culture was completed, 150 μL dimethyl sulfoxide (DMSO) was added to each well and incubated in the dark for 10 minutes. The OD value at 490 nm was used to represent the cell viability. It was used as the concentration basis for cell administration. The control group drug cytotoxicity test steps were the same as above, and the groups were divided into blank group and control drug different concentration gradient groups, with 200 mg / ml as the initial concentration, and 2-fold dilution was performed.

[0049] 3. Detection of expression levels of hair loss-related genes (EGF, FGF1, FGF2, VEGFA)

[0050] The cells were divided into a blank control group, a control group (1.25 mg / ml, 200 mg / ml*0.625%) and an experimental group (1.25 mg / ml, 200 mg / ml*0.625%). When the cell plating rate in the 6-well plate reached about 50-60%, the drug was administered. The drug concentration was the maximum safe concentration obtained from the cytotoxicity experiment results. After the end, the cells were placed in a (37°C, CO2) incubator for 24 hours. After the incubation, the cell supernatant was collected into a 1.5 mL EP tube, washed twice with 1 mL / well PBS, and 1 mL RNAiso Plus was added to each well. After pipetting and lysing the cells, the samples were collected, RNA was extracted, reverse transcribed to cDNA, and then fluorescent quantitative PCR was performed. 2 -△△CT Method to calculate the results.

[0051] 4. Statistical methods:

[0052] The results were expressed as mean ± standard deviation (Mean ± SD) and analyzed using SPSS statistical software, one-way analysis of variance or non-parametric test. P < 0.05 indicated statistically significant differences.

[0053] 3. Experimental Results

[0054] Animal experiment results:

[0055] 1. Effects of drugs on hair growth in depilatory mice

[0056] After depilation, the skin of mice turned pink (belonging to the resting phase). After 21 days, the hair in the depilated area on the back of mice in the depilation model group became sparse, soft, and dull, and flesh-colored skin could be seen. Figure 2The hair in the depilatory area of the positive control group was thick and shiny, and the length (P<0.01), weight (P<0.01), and hair growth score (P<0.05) of the newly grown hair were significantly better than those in the depilatory model group. The hair in the depilatory area of the experimental group was thick and shiny, and the length (P<0.01), weight (P<0.01), and hair growth score (P<0.01) of the newly grown hair were significantly better than those in the depilatory model group. The weight of the newly grown hair in the control group was significantly better than that in the depilatory model group (P<0.05), and there were no statistically significant differences in the length and hair growth score between the control group and the depilatory model group. The length (P<0.05), weight (P<0.01), and hair growth score (P<0.05) of the newly grown hair were significantly better in the experimental group than in the control group. The hair weight in the experimental group was significantly better than that in the positive control group (P<0.01), but the hair length and hair growth score were not statistically significant. As shown in Table 2 and Table 3, it can be seen that the positive drug, experimental drug and control drug all have the effect of promoting hair growth. From the experimental data, the positive drug and experimental drug are better than the control drug.

[0057] Table 2 Length and weight of new hair after treatment in different drug groups

[0058]

[0059] Note: ## compared with the hair removal model group, P < 0.01; @@ compared with the hair removal model group, P < 0.05, ** compared with the control group, P < 0.01, && compared with the control group, P < 0.05, $$ compared with the positive control group, P < 0.01.

[0060] Table 3 Hair growth scores after treatment in different drug groups

[0061]

[0062] Note: ##Compared with the hair removal model group, P<0.01; @@Compared with the hair removal model group, P<0.05; **Compared with the control group, P<0.05.

[0063] 2. Mouse skin hair follicles

[0064] like Figure 1 As shown, the model group had fewer hair follicles, fewer hair follicles in the growth phase, and inactive proliferation, while the number of hair follicles in the resting and catagen phases increased; the positive control group and the experimental group had more hair follicles in the growth phase and more active proliferation; the control group had more hair follicles than the model group, but less than the experimental group; there was little difference in the proliferation status of hair follicles among the four groups. Figure 1 .

[0065] Cell experiment results:

[0066] 1. Dermal papilla cytotoxicity test results

[0067] A cell viability value above 90% is considered a safe concentration. As shown in Table 4, the maximum safe concentration for cell administration in Example 1 is 0.625%, i.e., 200 mg / ml * 0.625% = 1.25 mg / ml. This concentration was used as the concentration for the experimental group. As shown in Table 5, the maximum safe concentration for cell administration of the control drug is 0.625%, i.e., 200 mg / ml * 0.625% = 1.25 mg / ml. This concentration was used as the concentration for the experimental group.

[0068] Table 4 Results of cytotoxicity test on hair papillae of experimental group drugs

[0069]

[0070] Table 5 Results of cytotoxicity test on hair papilla of control group drugs

[0071]

[0072] 2. Expression of hair-related genes (EGF, FGF1, FGF2, VEGFA)

[0073] Table 6 Expression levels of hair loss-related genes after different concentrations of drugs acted on dermal papilla cells

[0074]

[0075] Note: *Compared with the blank control group, P < 0.05, **Compared with the blank control group, P < 0.01, #Compared with the control group, P < 0.05, ##Compared with the control group, P < 0.01.

[0076] The expression levels of EGF, FGF2, and IL10 in the control group were statistically significant compared with the blank control group. In the experimental group, the expression levels of EGF, FGF1, FGF2, VEGFA, and IL10 were significantly increased, while the expression levels of IL12 and IFN-γ were significantly decreased. The expression levels of EGF, FGF1, FGF2, VEGFA, and IL10 in the experimental group were significantly increased, while the expression levels of IL12 and IFN-γ were significantly decreased. This suggests that the additional medication can increase the expression of genes associated with hair growth, promote the proliferation of dermal papilla cells, and contribute to hair growth. The experimental drug is superior to the control drug.

[0077] IV. Conclusion

[0078] This study evaluated the hair growth-promoting effects of experimental and control drugs using a hair loss mouse model. Results showed that the experimental drug, control group, and positive drug all promoted hair growth, with the positive and experimental drugs being superior to the control drug. This suggests that the therapeutic effect was significantly enhanced by adding pine needles, dandelion, and kelp to the control drug and modifying the dosage of the medicinal ingredients. The model group showed a decrease in the number of hair follicles, a decrease in the anagen phase, and inactive proliferation, while an increase in the number of telogen and catagen phase follicles. The positive control and experimental groups showed a greater number of anagen follicles and more active proliferation. The control group had a greater number of hair follicles than the model group, but fewer than the experimental group. The positive drug, experimental drug, and control group all increased the number of hair follicles, particularly in the anagen phase, with the experimental drug being more effective than the control drug.

[0079] VEGF (vascular endothelial growth factor) is a regulator of angiogenesis and vascular permeability. It is a glycosylated mitogen that acts specifically on endothelial cells, enhancing capillary permeability, inducing angiogenesis and endothelial cell growth. It stimulates hair growth by promoting nutrient supply to hair follicles. Studies have shown that VEGF expression is significantly reduced in hair follicles with alopecia compared to normal hair follicles. EGF is expressed in the outer root sheath of hair follicles, stimulating cell proliferation and hair follicle formation. EGF binds to the heterodimeric receptor EGFR / ErbB2. EGFR dimerization on the plasma membrane induces activation and trans-autophosphorylation of the EGFR tyrosine kinase. Tyrosine phosphorylation sites in activated EGFR form a complex network with various other signaling molecules to precisely control the hair cycle. The FGF family plays a crucial role in human hair follicle development, epidermal differentiation, and proliferation. FGF1, FGF, and their receptors are all located within or in close proximity to hair follicles. Studies have shown that the level of IFN-γ produced by peripheral blood mononuclear cells in patients with active alopecia areata is significantly higher than that in normal controls and inactive patients; the level of IL10 produced by patients with active alopecia areata is significantly lower than that in normal controls and inactive patients.

[0080] Therefore, we observed the gene expression levels of EGF, FGF1, FGF2, and VEGFA after applying topical medications at different concentrations to dermal papilla cells. The results showed that the expression levels of EGF, FGF2, and IL10 in the control group increased significantly compared with the blank control group, with statistical significance. In the experimental group, the expression levels of EGF, FGF1, FGF2, VEGFA, and IL10 increased significantly compared with the blank control group, while the expression levels of IL12 and IFN-γ decreased significantly compared with the blank control group, with statistical significance. In the experimental group, the expression levels of EGF, FGF1, FGF2, VEGFA, and IL10 increased significantly compared with the control group, while the expression levels of IL12 and IFN-γ decreased significantly compared with the control group, with statistical significance. This suggests that topical medications can increase the expression of genes related to hair growth, promote the proliferation of dermal papilla cells, and contribute to hair growth. The experimental medications were superior to the control medications. BRIEF DESCRIPTION OF THE DRAWINGS

[0081] Figure 1 The following are micrographs of HE-stained pathological findings of the skin tissues of mice in each group (scale bar = 500 μm), wherein Figure A is the model group; Figure B is the positive control group; Figure C is the experimental group; and Figure D is the control group.

[0082] Figure 2 Figures show the effects of different drugs on hair growth in hair-loss mice. Figure A shows the hair appearance of mice in the hair-loss model group, and Figure B shows the hair appearance of mice in the positive control group. Figure C shows the hair appearance of mice in the experimental group, and Figure D shows the hair appearance of mice in the control group. DETAILED DESCRIPTION

[0083] Example 1 (tincture)

[0084] 1. Prescription:

[0085] American ginseng 96.0g, dandelion 83.0g, salvia miltiorrhiza 71.0g, red ginseng 44.5g, astragalus 51.0g, Sichuan pepper 29.0g, pine needle 31.0g, kelp 28.0g, Panax notoginseng 21.5g, safflower 22.0g, and Chuanxiong 23.0g.

[0086] 2. Preparation method:

[0087] (1) Take the above raw materials, add 12 times the amount of water according to the proportion, and boil twice, each time for 3 hours;

[0088] (2) combining the two decoctions, filtering, and concentrating the filtrate under reduced pressure to a thick paste with a relative density of 1.1 at 25°C, and drying at 70°C to a dry paste;

[0089] (3) Take the dry paste prepared in step (2), add an appropriate amount of ethanol and dissolve it into a concentration equivalent to 1.1 g / ml of the raw material drug to prepare a tincture.

[0090] Example 2 (powder)

[0091] 1. Prescription:

[0092] American ginseng 106.0g, dandelion 91.7g, salvia miltiorrhiza 60.7g, red ginseng 37.1g, astragalus 38.3g, Sichuan pepper 23.0g, pine needle 30.4g, kelp 24.2g, Panax notoginseng 16.1g, safflower 19.1g, and Chuanxiong 22.5g.

[0093] 2. Preparation method:

[0094] (1) Take the above raw materials, add 15 times the amount of water according to the proportion, and boil twice, each time for 2 hours;

[0095] (2) combining the two decoctions, filtering, and concentrating the filtrate under reduced pressure to a thick paste with a relative density of 1.1 at 25°C, and drying at 60°C to a dry paste;

[0096] (3) The dry paste obtained in step (2) is crushed into fine powder to obtain a powder.

[0097] Example 3 (ointment)

[0098] 1. Prescription:

[0099] American ginseng 70.0g, dandelion 74.1g, salvia miltiorrhiza 66.6g, red ginseng 50.8g, astragalus 62.2g, Sichuan pepper 33.0g, pine needle 31.6g, kelp 26.6g, Panax notoginseng 26g, safflower 25.4g, and Chuanxiong 23.5g.

[0100] 2. Preparation method:

[0101] (1) Take the above raw materials, add 10 times the amount of water according to the proportion, and boil twice, each time for 4 hours;

[0102] (2) The two decoctions were combined, filtered, and the filtrate was concentrated under reduced pressure to a thick paste with a relative density of 1.2 at 25°C to prepare an ointment.

Claims

1. A topical medicament for treating seborrheic alopecia, the topical medicament comprising an active ingredient and a medically acceptable excipient, characterized in that: The active ingredient is made from the following raw materials in percentage by weight: American ginseng 13.6-22.8%, dandelion 12.8-20.8%, salvia miltiorrhiza 9.5-12.3%, red ginseng 7.9%-11.1%, astragalus 7.6-12.7%, zanthoxylum 4.4-7.3%, pine needle 4.7-7.4%, kelp 3.9-6.2%, Panax notoginseng 3.2-5.4%, safflower 3.3-5.5%, Chuanxiong 3.4-5.8%.

2. A topical medicament for treating seborrheic alopecia, comprising an active ingredient and a medically acceptable adjuvant, characterized in that: The active ingredient is made from the following raw materials in percentage by weight: American ginseng 19.2%, dandelion 16.6%, salvia miltiorrhiza 14.2%, red ginseng 8.9%, astragalus 10.2%, zanthoxylum 5.8%, pine needle 6.2%, kelp 5.6%, Panax notoginseng 4.3%, safflower 4.4%, and Chuanxiong 4.6%.

3. The external-use medicine for treating seborrheic alopecia according to claim 1 or 2, characterized in that: The external medicine is tincture, powder or ointment.

Images